Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, announces the availability of DecisionBase 8, an interactive decision tool that reveals the commercial opportunity of drugs in development and allows pharmaceutical and biotechnology organizations to compare those drugs with their own proprietary compounds. The unique database covers 35 diseases in a variety of therapeutic areas such as cardiovascular, central nervous system, oncology, immune and inflammatory disorders, infectious disease, psychiatric, metabolic, and other high-interest disease states.

  DecisionBase 8 allows users to:    -- Access information about and evaluate the potential for a specific       drug or disease.    -- Drill down to a rich data set to understand current treatment and       market dynamics.    -- Compare and contrast the unmet need and opportunity for proprietary       drug(s) against the future gold standard.  

"DecisionBase offers the most comprehensive coverage of drug markets available today," said Joe Walsh, vice president of business development at Decision Resources. "Each indication includes an executive summary, an epidemiology assessment, an unmet clinical need model, treatment decision trees, and an analysis of market trends--information that is vital to any drug development process."

Diabetic retinopathy, covered in DecisionBase for the first time, demonstrates an indication that is on the edge of exploding. Launches of novel drug therapies such as corticosteroid implants, oral PKC inhibitors, somatostatin analogues, and VEGF antagonists will fuel the meteoric rise of retinopathy sales from just under $45 million in 2002 to nearly $700 million in 2012. DecisionBase reveals the unmet need and commercial opportunity for pharmaceutical companies looking to break into this growth market.

Another growth market that DecisionBase 8 covers is Hepatitis B. With a growing number of patients presenting with advanced disease, as well as a need for therapies that are effective against lamivudine-resistant virus, the market could grow to nearly $1.1 billion in 2007 and reach almost $2.1 billion in 2012 with Bristol Myers-Squibb's entecavir becoming the gold standard in 2007 and holding that position through 2012.

About DecisionBase 8

DecisionBase 8 is built on insights from leading published studies, interviews with hundreds of thought-leading physicians and researchers from seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan), and input from Decision Resources' staff of therapeutic area experts. Its breadth of coverage, depth of analysis, and flexible modeling make DecisionBase an ideal tool for organizations looking to make strategic choices, model options, forecast potential, license new drugs, and achieve commercial success.

About Decision Resources

Decision Resources, Inc., (www.decisionresources.com) is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Xolair Will Lead the Growth of the Asthma Drug Market With Sales of $3.3 Billion in 2012

View Now